Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
New England Journal of Medicine · 10.04.2025 · 392 (14) · 1363-1373
DOI: 10.1056/nejmoa2416112 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 10.04.2025. Verfasst von Isabelle Mahé und 35 weiteren Autor:innen. Beteiligte Einrichtung: Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Louis Mourier, Service de Médecine Interne, Colombes, France. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Hemorrhage, Neoplasms, Pulmonary Embolism. Die Arbeit wurde bisher 177-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Bristol-Myers Squibb–Pfizer Alliance.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Louis Mourier, Service de Médecine Interne, Colombes, France.
- Université Paris Cité, Paris.
- INSERM Unité Mixte de Recherche S970, Paris Cardiovascular Research Center, Team "Endotheliopathy and Hemostasis Disorders," Paris.
- Investigation Network on Venous Thrombo-Embolism-French Clinical Research Infrastructure Network, Saint-Étienne, France.
- Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa.
- Centre Georges-François Leclerc, Dijon, France.
ORCID-Profile: Isabelle Mahé, Marc Carrier, Juan J López-Núñez, Menno V Huisman, Frederikus A Klok, Laurent Bertoletti
Förderung
- Bristol-Myers Squibb–Pfizer Alliance
Zitieren
APA
Mahé, I., Carrier, M., Mayeur, D., Chidiac, J., Vicaut, E., Falvo, N., Sanchez, O., Grange, C., Monreal, M., López-Núñez, J. J., Otero-Candelera, R., Le Gal, G., Yeo, E., Righini, M., Robert-Ebadi, H., Huisman, M. V., Klok, F. A., Westerweel, P., Agnelli, G., …, & API-CAT Investigators (2025). Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. New England Journal of Medicine, 392(14), 1363-1373. https://doi.org/10.1056/nejmoa2416112
Vancouver
Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, et al. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. New England Journal of Medicine. 2025;392(14):1363-1373. doi:10.1056/nejmoa2416112
BibTeX
@article{Mah2025,
author = {Mahé, Isabelle and Carrier, Marc and Mayeur, Didier and Chidiac, Jean and Vicaut, Eric and Falvo, Nicolas and Sanchez, Olivier and Grange, Claire and Monreal, Manuel and López-Núñez, Juan J and Otero-Candelera, Remedios and Le Gal, Grégoire and Yeo, Erik and Righini, Marc and Robert-Ebadi, Helia and Huisman, Menno V and Klok, Frederikus A and Westerweel, Peter and Agnelli, Giancarlo and Becattini, Cecilia and Bamias, Aristotelis and Syrigos, Kostas and Szmit, Sebastian and Torbicki, Adam and Verhamme, Peter and Maraveyas, Anthony and Cohen, Alexander T and Ay, Cihan and Chapelle, Céline and Meyer, Guy and Couturaud, Francis and Mismetti, Patrick and Girard, Philippe and Bertoletti, Laurent and Laporte, Silvy and API-CAT Investigators, API-CAT Investigators},
title = {Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {14},
pages = {1363--1373},
doi = {10.1056/nejmoa2416112}
}
EUVIMED